OpenAlex
PricingAboutJobs
Log inGet started
Work

Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis

HTML

Year: 2012
Type: article
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-11-3145
Authors: John Mascarenhas, Ronald Hoffman
Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: ruxolitinib, primary myelofibrosis, myeloproliferative neoplasms, JAK2 mutation, JAK1/2 inhibitor, splenomegaly, essential thrombocythemia, polycythemia vera, FDA approval, hematologic malignancies, disease-related symptoms
SDG: Good health and well-being

Open Access status: closed

Funder: National Cancer Institute
Award: Myeloproliferative Neoplasms-Research Consortium
OpenAlex ID: W2170169485
FWCI: 8.183
Cites: 35
Cited by: 291
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms